Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Mediators Inflamm. 2018 Feb 12;2018:2403935. doi: 10.1155/2018/2403935. eCollection 2018.
Spondyloarthropathy (SpA) is a unique type of joint inflammation characterized by coexisting erosive bone damage and pathological new bone formation. Previous genetic association studies have demonstrated that several cytokine pathways play a critical role in the pathogenesis of ankylosing spondylitis (AS), psoriatic arthritis (PsA), and other types of SpA. In addition to several well-known proinflammatory cytokines, recent studies suggest that IL-17 plays a pivotal role in the pathogenesis of SpA. Further evidence from human and animal studies have defined that IL-17 and IL-17-producing cells contribute to tissue inflammation, autoimmunity, and host defense, leading to the following pathologic events associated with SpA. Recently, several clinical trials targeting IL-17 pathways demonstrated the positive response of IL-17 blockade in treating AS, indicating a great potential of IL-17-targeting therapy in SpA. In this review article, we have discussed the contributing role of IL-17 and different IL-17-producing cells in the pathogenesis of SpA and provided an outline of therapeutic application of the IL-17 blockade in the treatment of SpA. Other targeted cytokines associated with IL-17 axis in SpA will also be included.
脊柱关节炎（SpA）是一种独特类型的关节炎症，其特征为同时存在侵蚀性骨损伤和病理性新骨形成。既往的遗传关联研究表明，几种细胞因子途径在强直性脊柱炎（AS）、银屑病关节炎（PsA）和其他类型的 SpA 的发病机制中起关键作用。除了几种众所周知的促炎细胞因子外，最近的研究表明，IL-17 在 SpA 的发病机制中发挥着重要作用。来自人类和动物研究的进一步证据表明，IL-17 和产生 IL-17 的细胞有助于组织炎症、自身免疫和宿主防御，导致与 SpA 相关的以下病理事件。最近，几项针对 IL-17 途径的临床试验表明，IL-17 阻断在治疗 AS 中的积极反应，表明 IL-17 靶向治疗在 SpA 中有很大的潜力。在这篇综述文章中，我们讨论了 IL-17 和不同的产生 IL-17 的细胞在 SpA 发病机制中的作用，并概述了 IL-17 阻断在治疗 SpA 中的治疗应用。还将包括与 SpA 中 IL-17 轴相关的其他靶向细胞因子。
